Cytokine profiles in polycythemia vera and essential thrombocythemia patients: Clinical implications

Experimental Hematology

Volumn 42, Issue 5, 2014, Pages 360-368

  Pourcelot, Emmanuel ^a,b   Trocme, Candice ^a   Mondet, Julie ^a,b   Bailly, Sébastien ^a   Toussaint, Bertrand ^a,b   Mossuz, Pascal ^a,b  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b LABORATOIRE TIMC IMAG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; JANUS KINASE 2; MONOCYTE CHEMOTACTIC PROTEIN 1; PHENYLALANINE; PLATELET DERIVED GROWTH FACTOR BB; TUMOR NECROSIS FACTOR ALPHA; VALINE; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; DISEASE ASSOCIATION; HUMAN; IMMUNOASSAY; LIMIT OF QUANTITATION; MUTATION; PHENOTYPE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; THROMBOCYTHEMIA;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; CYTOKINES; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION, MISSENSE; POLYCYTHEMIA VERA; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 84901071488     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2014.01.006     Document Type: Article

References (27)

1. Adamson J.W., Fialkow P.J., Murphy S., Prchal J.F., Steinmann L. Polycythemia vera: stem-cell and probable clonal origin of the disease. NEngl J Med 1976, 295:913-916.
2. Campbell P.J., Green A.R. The myeloproliferative disorders. N Engl JMed 2006, 355:2452-2466.
3. Marchioli R., Finazzi G., Landolfi R., et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005, 23:2224-2232.
4. Spivak J.L. Polycythemia vera: myths, mechanisms, and management. Blood 2002, 100:4272-4290.
5. Passamonti F., Rumi E., Pietra D., et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006, 107:3676-3682.
6. Landolfi R. Bleeding and thrombosis in myeloproliferative disorders. Curr Opin Hematol 1998, 5:327-331.
7. Elliott M.A., Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005, 128:275-290.
8. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779-1790.
9. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
10. James C., Ugo V., Le Couedic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
11. Harrison C., Kiladjian J.J., Al-Ali H.K., et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012, 366:787-798.
12. Verstovsek S., Kantarjian H., Mesa R.A., et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. 2010. N Engl J Med 2010, 363:1117-1127.
13. Pardanani A., Gotlib J.R., Jamieson C., et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J ClinOncol 2011, 29:789-796.
14. Verstovsek S., Mesa R.A., Gotlib J., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012, 366:799-807.
15. Boissinot M., Cleyrat C., Vilaine M., et al. Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F. Oncogene 2010, 30:990-1001.
16. Tefferi A., Vaidya R., Caramazza D., et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011, 29:1356-1363.
17. Chowdhury F., Williams A., Johnson P. Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling. J Immunol Methods 2009, 340:55-64.
18. Kokkonen H., Soderstrom I., Rocklov J., et al. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum 2010, 62:383-391.
19. Wickenhauser C., Thiele J., Lorenzen J., et al. Polycythemia vera megakaryocytes but not megakaryocytes from normal controls and patients with smokers polyglobuly spontaneously express IL-6 and IL-6R and secrete IL-6. Leukemia 1999, 13:327-334.
20. Hermouet S., Godard A., Pineau D., et al. Abnormal production of interleukin (IL)-11 and IL-8 in polycythaemia vera. Cytokine 2002, 20:178-183.
21. Musolino C., Calabro L., Bellomo G., et al. Soluble angiogenic factors: implications for chronic myeloproliferative disorders. Am J Hematol 2002, 69:159-163.
22. Fleischman A.G., Aichberger K.J., Luty S.B., et al. TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood 2011, 118:6392-6398.
23. Reitsma P.H., Rosendaal F.R. Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study. J Thromb Haemost 2004, 2:619-622.
24. Poredos P., Jezovnik M.K. In patients with idiopathic venous thrombosis, interleukin-10 is decreased and related to endothelial dysfunction. Heart Vessels 2011, 26:596-602.
25. vanAken B.E., Reitsma P.H., Rosendaal F.R. Interleukin 8 and venous thrombosis: evidence for a role of inflammation in thrombosis. Br J Haematol 2002, 116:173-177.
26. Christiansen S.C., Naess I.A., Cannegieter S.C., et al. Inflammatory cytokines as risk factors for a first venous thrombosis: a prospective population-based study. PLoS Med 2006, 3:e334.
27. vanAken B.E., den Heijer M., Bos G.M., van Deventer S.J., Reitsma P.H. Recurrent venous thrombosis and markers of inflammation. Thromb Haemost 2002, 83:536-539.